Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Csl Ltd ADR (CSLLY)

Csl Ltd ADR (CSLLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 47,250,660
  • Shares Outstanding, K 1,941,276
  • Annual Sales, $ 15,558 M
  • Annual Income, $ 3,002 M
  • EBIT $ 0 M
  • EBITDA $ 5,151 M
  • 60-Month Beta 0.80
  • Price/Sales 3.00
  • Price/Cash Flow 11.00
  • Price/Book 2.18
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/19/25
  • Annual Dividend & Yield (Fwd) 0.60 (2.49%)
  • Most Recent Dividend 0.300 on 03/11/26
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.8300 +6.61%
on 03/19/26
28.0000 -13.07%
on 03/02/26
-1.7150 (-6.58%)
since 02/27/26
3-Month
22.8300 +6.61%
on 03/19/26
33.5316 -27.41%
on 02/10/26
-4.8100 (-16.50%)
since 12/26/25
52-Week
22.8300 +6.61%
on 03/19/26
44.8550 -45.74%
on 07/29/25
-15.3450 (-38.67%)
since 03/27/25

Most Recent Stories

More News
CSL announces expansion of Illinois plasma therapy manufacturing facility

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018

CSLLY : 24.3400 (+1.16%)
Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited

Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is a global biopharma...

DB : 28.37 (-2.10%)
CSLLY : 24.3400 (+1.16%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 240.45 (+0.51%)
LLY : 878.24 (-2.09%)
ABBV : 209.40 (-0.81%)
GSK : 53.84 (-0.19%)
CSLLY : 24.3400 (+1.16%)
PFE : 27.04 (-1.92%)
SNY : 46.78 (+0.34%)
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit ...

CSLLY : 24.3400 (+1.16%)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0 ™ principles with sustainable design to transform plasma manufacturing

CSLLY : 24.3400 (+1.16%)
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

SUMMIT, N.J. , Oct. 21, 2025 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed...

CSL : 325.58 (-2.42%)
CSLLY : 24.3400 (+1.16%)
Jarden Remains a Buy on CSL (CMXHF)

In a report released on October 13, Steven Wheen from Jarden maintained a Buy rating on CSL, with a price target of A$298.13. The company’s shares closed yesterday at $131.65.Elevate Your Investing Strategy:...

CMXHF : 95.5600 (-0.47%)
CSLLY : 24.3400 (+1.16%)
CSL (CMXHF) Receives a Hold from Bell Potter

Bell Potter analyst Thomas Wakim maintained a Hold rating on CSL today and set a price target of A$230.00. The company’s shares closed yesterday at $131.65.Elevate Your Investing Strategy: Take advantage...

CMXHF : 95.5600 (-0.47%)
CSLLY : 24.3400 (+1.16%)
UBS Keeps Their Buy Rating on CSL (CMXHF)

UBS analyst Marcus Curley maintained a Buy rating on CSL today and set a price target of A$300.00. The company’s shares closed today at $131.65.Elevate Your Investing Strategy: Take advantage of TipRanks...

CMXHF : 95.5600 (-0.47%)
CSLLY : 24.3400 (+1.16%)
CLSA Keeps Their Buy Rating on CSL (CMXHF)

In a report released today, Andrew Paine from CLSA maintained a Buy rating on CSL, with a price target of A$275.00. The company’s shares closed last Friday at $130.18.Elevate Your Investing Strategy:...

CMXHF : 95.5600 (-0.47%)
CSLLY : 24.3400 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived...

See More

Key Turning Points

3rd Resistance Point 24.8340
2nd Resistance Point 24.6470
1st Resistance Point 24.4935
Last Price 24.3400
1st Support Level 24.1530
2nd Support Level 23.9660
3rd Support Level 23.8125

See More

52-Week High 44.8550
Fibonacci 61.8% 36.4414
Fibonacci 50% 33.8425
Fibonacci 38.2% 31.2435
Last Price 24.3400
52-Week Low 22.8300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.